Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
Want to see RNAC full AI Analyst Report?
Top Page
Cartesian Therapeutics
(NASDAQ:RNAC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$6.50
▼(-7.67% Downside)
Action:ReiteratedDate:04/30/26
The score is primarily weighed down by weak financial performance (shrinking revenue, very large losses, and heavy ongoing cash burn) alongside a strained balance sheet signaled by negative equity. Technicals add modest support from neutral momentum indicators, but the broader downtrend (price below key moving averages) and limited valuation support (negative P/E; no dividend yield provided) keep the overall score low.
Positive Factors
mRNA-engineered cell therapy platform
Cartesian’s core mRNA-based platform that reprograms patient immune cells ex vivo is a durable fundamental advantage. Non‑permanent modification can reduce long‑term safety/regulatory hurdles versus permanent gene edits, enabling repeated dosing and broader applicability across autoimmune indications if clinical proof emerges.
Negative Factors
Heavy operating cash burn
Persistent, large negative operating and free cash flow indicates the business cannot self‑fund development. This creates ongoing dependence on external financing or partnerships, increasing dilution risk and potentially forcing pace reductions in clinical programs if capital access tightens over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
mRNA-engineered cell therapy platform
Cartesian’s core mRNA-based platform that reprograms patient immune cells ex vivo is a durable fundamental advantage. Non‑permanent modification can reduce long‑term safety/regulatory hurdles versus permanent gene edits, enabling repeated dosing and broader applicability across autoimmune indications if clinical proof emerges.
Read all positive factors
Cartesian Therapeutics (RNAC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$171.51M
Dividend YieldN/A
Average Volume (3M)261.29K
Price to Earnings (P/E)―
Beta (1Y)2.27
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees66
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.46
Shares Outstanding26,509,024
10 Day Avg. Volume211,613
30 Day Avg. Volume261,294
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue33.27
Enterprise Value/Gross Profit-5.32
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$34.00Price Target Upside382.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.29
Revenue Forecast (FY)$672.57K
Cartesian Therapeutics Business Overview & Revenue Model
Company Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy p...
How the Company Makes Money
null...
Cartesian Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.77M | 2.80M | 38.91M | 26.00M | 110.78M | 85.08M |
| Gross Profit | -11.10M | 2.80M | 38.91M | 26.00M | 108.74M | 85.08M |
| EBITDA | -40.76M | -86.70M | -75.99M | -235.03M | 39.84M | -5.16M |
| Net Income | -151.77M | -130.30M | -77.42M | -219.71M | 35.38M | -25.69M |
Balance Sheet | ||||||
| Total Assets | 288.39M | 296.41M | 435.02M | 305.05M | 165.89M | 159.88M |
| Cash, Cash Equivalents and Short-Term Investments | 118.64M | 125.14M | 212.61M | 76.91M | 134.60M | 128.06M |
| Total Debt | 11.86M | 12.68M | 13.98M | 10.96M | 37.92M | 35.28M |
| Total Liabilities | 436.51M | 422.65M | 441.82M | 745.23M | 72.06M | 137.36M |
| Stockholders Equity | -148.12M | -126.24M | -6.80M | -440.18M | 93.83M | 22.52M |
Cash Flow | ||||||
| Free Cash Flow | -77.37M | -79.39M | -32.77M | -51.37M | -32.83M | -61.47M |
| Operating Cash Flow | -72.97M | -73.94M | -23.67M | -51.16M | -31.63M | -60.38M |
| Investing Cash Flow | -4.41M | -5.45M | -8.74M | 34.61M | -15.00M | -17.14M |
| Financing Cash Flow | 15.64M | -8.05M | 168.43M | -13.14M | 39.22M | 52.90M |
Cartesian Therapeutics Technical Analysis
Positive
7.04
Price Trends
6.82
Positive
7.07
Negative
8.68
Negative
Market Momentum
-0.15
Negative
57.61
Neutral
60.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAC, the sentiment is Positive. The current price of 7.04 is above the 20-day moving average (MA) of 6.23, above the 50-day MA of 6.82, and below the 200-day MA of 8.68, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 57.61 is Neutral, neither overbought nor oversold. The STOCH value of 60.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNAC.
Cartesian Therapeutics Risk Analysis
Cartesian Therapeutics disclosed 45 risk factors in its most recent earnings report. Cartesian Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cartesian Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $380.67M | 9.56 | 27.78% | ― | -0.91% | 1.03% | |
57 Neutral | $432.62M | -1.84 | -46.34% | ― | ― | 2.37% | |
52 Neutral | $1.17B | -3.63 | -189.50% | ― | ― | 10.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $219.53M | -1.93 | -51.35% | ― | -49.53% | -81.33% | |
47 Neutral | $685.33M | -0.19 | 72.70% | ― | ― | -880.05% | |
44 Neutral | $171.51M | -1.44 | 279.62% | ― | ― | ― |
* Healthcare Sector Average
RNAC
Cartesian Therapeutics
6.47
-5.80
-47.27%
PBYI
Puma Biotechnology
7.48
4.40
142.86%
DBVT
DBV Technologies SA - American
20.30
11.69
135.77%
VYGR
Voyager Therapeutics
3.64
0.09
2.54%
AVIR
Atea Pharmaceuticals
5.43
2.44
81.61%
VOR
Vor Biopharma
14.03
0.81
6.13%
Cartesian Therapeutics Corporate Events
Executive/Board Changes
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
Neutral
Mar 30, 2026
On March 26, 2026, Cartesian Therapeutics, Inc. disclosed that Board member Murat Kalayoglu, M.D., Ph.D., intends to resign from the Board effective March 31, 2026, after serving since 2023. Kalayoglu, who chaired the Science and Technology Commit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.